- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Filament Health Announces Third Quarter 2025 Financial Results And Operational Highlights | 2 | CNW | ||
| 11.08. | Filament Health Corp. reports Q2 results | 2 | Seeking Alpha | ||
| FILAMENT HEALTH Aktie jetzt für 0€ handeln | |||||
| 11.08. | Filament Health Announces Second Quarter 2025 Financial Results And Operational Highlights | 1 | CNW | ||
| 31.07. | Filament Health Announces First-ever Compassionate Use Approval For Psilocybin In The European Union | 1 | CNW | ||
| 24.07. | Filament Health Announces Two Phase 2 Research Trials In Partnership With University College London | 1 | CNW | ||
| 08.07. | Jaguar Health, Inc.: Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health | 521 | ACCESS Newswire | Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 /
Jaguar Health, Inc.
(NASDAQ:JAGX)
... ► Artikel lesen | |
| 07.07. | Filament Health Announces Fda Authorization Of Phase 2 Clinical Trial Studying Psilocybin For Alcohol Use Disorder And Post-traumatic Stress Disorder In Veterans And First Responders | 1 | CNW | ||
| 17.06. | Filament Health Enters Into Exclusive License Agreement With University Of Alabama At Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder | 2 | CNW | ||
| 11.06. | Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder | 1 | CNW | ||
| 28.05. | Filament Health Announces Transition From Otcqb To Otc Pink Limited | 3 | CNW | ||
| 22.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.05.2025 | 777 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.05.2025.ISIN NameCA31685W1068 FILAMENT... ► Artikel lesen | |
| 22.05. | XFRA 7QS: AUSSETZUNG/SUSPENSION | 247 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILAMENT HEALTH... ► Artikel lesen | |
| 20.05. | Filament Health Corp: Filament shares to delist from Cboe Canada May 21 | 1 | Stockwatch | ||
| 19.05. | Filament Health Corp.: Filament Health Announces Voluntary Delisting From Cboe Canada | 192 | PR Newswire | VANCOUVER, BC, May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 09.05. | Filament Health Corp.: Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights | 102 | PR Newswire | VANCOUVER, BC, May 8, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 04.04. | Filament Health Corp.: Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada | 175 | PR Newswire | Financing driven by existing investor Negev and Filament's Board of Directors
Company also announces intention to voluntarily delist from Cboe Canada
VANCOUVER... ► Artikel lesen | |
| 01.04. | Filament Health Corp.: Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights | 138 | PR Newswire | VANCOUVER, BC, April 1, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
| 17.03. | Filament Health Corp.: Filament Health Announces Positive Data From Phase 2 Study Of Pex010 In Patients With Alcohol Use Disorder | 114 | PR Newswire | Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botanical psilocybin... ► Artikel lesen | |
| 06.02. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference | 494 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as... ► Artikel lesen | |
| 07.01. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum | 497 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 29,060 | +5,94 % | Bayer: Neue Daten aus Phase-III-Studie mit Finerenon | Bayers Medikament Finerenon hat in der Phase-III-Studie FINE-ONE bei Erwachsenen mit chronischer Nierenerkrankung in Verbindung mit Typ-1-Diabetes eine statistisch signifikante Reduzierung des Albumin-Kreatinin-Verhältnisses... ► Artikel lesen | |
| AURORA CANNABIS | 3,935 | +0,51 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Fiscal 2026 Second Quarter Results | Expands YoY Global Medical Cannabis Net Revenue 1 by 15% to Record $70.5 million
Increases International Medical Cannabis Net Revenue 1 by 22% to... ► Artikel lesen | |
| CANOPY GROWTH | 1,022 | +0,79 % | Cannabis-Aktien im Fokus: Canopy Growth und Bioxyne - alles dreht sich um strategische Umsetzung! | ||
| TILRAY BRANDS | 1,064 | +0,61 % | Tilray Brands, Inc.: Tilray Brands Condemns Misguided Prohibitionist Measures and Champions Responsible Hemp Regulations that Keep Consumers Safe and Businesses Thriving | NEW YORK, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray Brands" or "Tilray") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of... ► Artikel lesen | |
| INNOCAN PHARMA | 9,750 | -0,51 % | InnoCan Pharma: Big News noch vor dem Nasdaq-IPO? | ||
| CRONOS GROUP | 2,170 | -1,27 % | Cronos signals revenue boost potential with 70% flower capacity increase amid international momentum | ||
| SYNBIOTIC | 2,350 | +0,21 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC begrüßt Antrag der Grünen zum Nutzhanfliberalisierungsgesetz und fordert Sachlichkeit in der Medizinalcannabis-Debatte | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Stellungnahme
SYNBIOTIC begrüßt Antrag der Grünen zum Nutzhanfliberalisierungsgesetz und fordert Sachlichkeit in der Medizinalcannabis-Debatte... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 6,090 | +0,08 % | Green Thumb Industries Reports Third Quarter 2025 Results | CHICAGO and VANCOUVER, British Columbia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| CHRISTINA LAKE CANNABIS | 0,020 | 0,00 % | Christina Lake Cannabis Corp.: Christina Lake Cannabis Announces Debenture Extension | VANCOUVER, British Columbia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Christina Lake Cannabis Corp. (the "Company" or "CLC" or "Christina Lake Cannabis") (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT: CLB) announces... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 123,25 | +1,32 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy | Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 120,60 | +2,25 % | Jazz Pharmaceuticals präsentiert neue Daten zur Hirntumorforschung auf SNO-Jahrestagung | ||
| JAGUAR HEALTH | 1,720 | 0,00 % | Jaguar Health, Inc.: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology | Results of ongoing investigator-initiated proof-of-concept trial of crofelemer in United Arab Emirates (UAE) demonstrate disease progression modification and reduction of total parenteral support (PS)... ► Artikel lesen | |
| TRULIEVE CANNABIS | 6,085 | +1,76 % | Trulieve Cannabis just got a massive price target raise from this analyst | ||
| CORBUS PHARMACEUTICALS | 9,250 | -3,65 % | Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report | ||
| AVALO THERAPEUTICS | 13,160 | -0,75 % | Avalo Therapeutics GAAP EPS of -$2.19 |
FILAMENT HEALTH CORP gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FILAMENT HEALTH CORP finden Sie auf Wallstreet Online.